1. Home
  2. DFNS vs MRKR Comparison

DFNS vs MRKR Comparison

Compare DFNS & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DFNS

T3 Defense Inc. Common Stock

N/A

Current Price

$0.60

Market Cap

27.2M

ML Signal

N/A

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.29

Market Cap

23.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFNS
MRKR
Founded
2013
1999
Country
United States
United States
Employees
15
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.2M
23.0M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
DFNS
MRKR
Price
$0.60
$1.29
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$11.25
AVG Volume (30 Days)
1.2M
111.0K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.61
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$621.68
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.62
$0.81
52 Week High
$2.68
$4.07

Technical Indicators

Market Signals
Indicator
DFNS
MRKR
Relative Strength Index (RSI) 19.61 45.42
Support Level N/A $1.14
Resistance Level $2.44 $1.43
Average True Range (ATR) 0.12 0.10
MACD -0.02 0.01
Stochastic Oscillator 17.99 53.54

Price Performance

Historical Comparison
DFNS
MRKR

About DFNS T3 Defense Inc. Common Stock

T3 Defense Inc is a holding company that acquires and operates mission-critical defense businesses involved in national security programs. It focuses on manufacturers with tough customer relationships and solid order backlogs, often capacity-and resource-constrained and specialized areas such as drones and autonomous vehicles, counter-drone systems, main manufacturing, tactical robotics, and AI software and system integration. Through disciplined acquisitions, centralized capital and ideas, and decentralized day-to-day operations, it aims to strengthen essential defense capabilities and build long-term value.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Share on Social Networks: